Body mass index and risk of dying from a bloodstream infection: A Mendelian randomization study.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
18
12
2019
accepted:
08
10
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
26
1
2021
Statut:
epublish
Résumé
In observational studies of the general population, higher body mass index (BMI) has been associated with increased incidence of and mortality from bloodstream infection (BSI) and sepsis. On the other hand, higher BMI has been observed to be apparently protective among patients with infection and sepsis. We aimed to evaluate the causal association of BMI with risk of and mortality from BSI. We used a population-based cohort in Norway followed from 1995 to 2017 (the Trøndelag Health Study [HUNT]), and carried out linear and nonlinear Mendelian randomization analyses. Among 55,908 participants, the mean age at enrollment was 48.3 years, 26,324 (47.1%) were men, and mean BMI was 26.3 kg/m2. During a median 21 years of follow-up, 2,547 (4.6%) participants experienced a BSI, and 451 (0.8%) died from BSI. Compared with a genetically predicted BMI of 25 kg/m2, a genetically predicted BMI of 30 kg/m2 was associated with a hazard ratio for BSI incidence of 1.78 (95% CI: 1.40 to 2.27; p < 0.001) and for BSI mortality of 2.56 (95% CI: 1.31 to 4.99; p = 0.006) in the general population, and a hazard ratio for BSI mortality of 2.34 (95% CI: 1.11 to 4.94; p = 0.025) in an inverse-probability-weighted analysis of patients with BSI. Limitations of this study include a risk of pleiotropic effects that may affect causal inference, and that only participants of European ancestry were considered. Supportive of a causal relationship, genetically predicted BMI was positively associated with BSI incidence and mortality in this cohort. Our findings contradict the "obesity paradox," where previous traditional epidemiological studies have found increased BMI to be apparently protective in terms of mortality for patients with BSI or sepsis.
Sections du résumé
BACKGROUND
In observational studies of the general population, higher body mass index (BMI) has been associated with increased incidence of and mortality from bloodstream infection (BSI) and sepsis. On the other hand, higher BMI has been observed to be apparently protective among patients with infection and sepsis. We aimed to evaluate the causal association of BMI with risk of and mortality from BSI.
METHODS AND FINDINGS
We used a population-based cohort in Norway followed from 1995 to 2017 (the Trøndelag Health Study [HUNT]), and carried out linear and nonlinear Mendelian randomization analyses. Among 55,908 participants, the mean age at enrollment was 48.3 years, 26,324 (47.1%) were men, and mean BMI was 26.3 kg/m2. During a median 21 years of follow-up, 2,547 (4.6%) participants experienced a BSI, and 451 (0.8%) died from BSI. Compared with a genetically predicted BMI of 25 kg/m2, a genetically predicted BMI of 30 kg/m2 was associated with a hazard ratio for BSI incidence of 1.78 (95% CI: 1.40 to 2.27; p < 0.001) and for BSI mortality of 2.56 (95% CI: 1.31 to 4.99; p = 0.006) in the general population, and a hazard ratio for BSI mortality of 2.34 (95% CI: 1.11 to 4.94; p = 0.025) in an inverse-probability-weighted analysis of patients with BSI. Limitations of this study include a risk of pleiotropic effects that may affect causal inference, and that only participants of European ancestry were considered.
CONCLUSIONS
Supportive of a causal relationship, genetically predicted BMI was positively associated with BSI incidence and mortality in this cohort. Our findings contradict the "obesity paradox," where previous traditional epidemiological studies have found increased BMI to be apparently protective in terms of mortality for patients with BSI or sepsis.
Identifiants
pubmed: 33196656
doi: 10.1371/journal.pmed.1003413
pii: PMEDICINE-D-19-04607
pmc: PMC7668585
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003413Subventions
Organisme : Wellcome Trust
ID : 204623/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00002/7
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/1
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : K08 GM115859
Pays : United States
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: SB is a paid statistical reviewer for PLOS Medicine. HCP has current or prior grant funding from the NIH, AHRQ, and the US Department of Veterans Affairs. The other authors have declared that no competing interests exist.
Références
Int J Epidemiol. 2019 Jun 1;48(3):691-701
pubmed: 30325422
Obes Rev. 2018 Jul;19(7):917-930
pubmed: 29527783
Obesity (Silver Spring). 2013 Dec;21(12):E762-9
pubmed: 23526732
Epidemiology. 2004 Sep;15(5):615-25
pubmed: 15308962
BMC Infect Dis. 2017 Jul 12;17(1):493
pubmed: 28701159
PLoS One. 2016 Apr 28;11(4):e0154599
pubmed: 27124716
BMJ Open. 2018 Sep 12;8(9):e021979
pubmed: 30209156
Lancet. 2016 Aug 20;388(10046):776-86
pubmed: 27423262
Am J Epidemiol. 2011 Jun 15;173(12):1392-403
pubmed: 21555716
Ann Intern Med. 2019 Jun 18;170(12):845-852
pubmed: 31083728
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
Am J Med. 2015 Apr;128(4):334-6
pubmed: 25460531
Crit Care Med. 2019 May;47(5):643-650
pubmed: 30789403
Nature. 2019 May;569(7755):260-264
pubmed: 31068725
Shock. 2016 Apr;45(4):349-58
pubmed: 26513706
BMJ. 2018 Jul 12;362:k601
pubmed: 30002074
Crit Care Med. 2014 Aug;42(8):1766-74
pubmed: 24717466
Eur J Epidemiol. 2017 May;32(5):377-389
pubmed: 28527048
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Hum Mol Genet. 2018 Oct 15;27(20):3641-3649
pubmed: 30124842
Crit Care. 2016 Aug 05;20(1):244
pubmed: 27492089
Clin Microbiol Infect. 2013 Jun;19(6):501-9
pubmed: 23473333
Sci Rep. 2019 Jan 22;9(1):309
pubmed: 30670737
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Int J Obes (Lond). 2018 Apr;42(4):801-807
pubmed: 29081504
PLoS One. 2013 Dec 04;8(12):e79344
pubmed: 24324580
BMJ. 2019 Mar 26;364:l1042
pubmed: 30957776
EBioMedicine. 2019 Mar;41:85-90
pubmed: 30772304
Epidemiology. 2013 May;24(3):461-2
pubmed: 23549182
Respir Care. 2015 Jul;60(7):983-91
pubmed: 25691767
Eur J Epidemiol. 2020 Apr;35(4):347-354
pubmed: 32307655
Econ Hum Biol. 2014 Mar;13:99-106
pubmed: 24388127
BMC Anesthesiol. 2017 Aug 31;17(1):118
pubmed: 28859605
Epidemiology. 2015 May;26(3):411-3
pubmed: 25835137
Crit Care. 2013 Apr 17;17(2):R72
pubmed: 23594407
Int J Epidemiol. 2017 Oct 1;46(5):1573-1581
pubmed: 28637260
Crit Care Med. 2019 Sep;47(9):e790
pubmed: 31415325
Int J Epidemiol. 2018 Feb 1;47(1):226-235
pubmed: 29040562
BMC Anesthesiol. 2017 Oct 25;17(1):147
pubmed: 29070011
Am J Hum Genet. 2015 Jun 4;96(6):926-37
pubmed: 26027497
Int J Epidemiol. 2008 Oct;37(5):1161-8
pubmed: 18463132
JAMA. 2012 Aug 8;308(6):581-90
pubmed: 22871870
Am J Med. 2010 Sep;123(9):819-28
pubmed: 20800151
Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):585-591
pubmed: 27864622